How 340B In Big Health Systems is Hurting Patients

The 340B Drug Pricing Program is meant to provide patients in need or patients in poorer areas with access to prescription drugs at significantly discounted prices. Is that what the program accomplishes currently? Join Rose Gerber and her guests Ted Okon and Nicolas Ferreyros on October 12, 2022 at 12 p.m. ET, for a discussion about this federal program gone awry.

The current structure of the 340B program allows hospitals to reap massive profits by purchasing drugs at a discount, then keeping those profits instead of passing them on to the patients who need them. These funds allow large hospitals to purchase competitors and force community practices out of business, stifling competition and increasing the cost of care for everyone. COA’s Executive Director Ted Okon and Managing Director Nicolas Ferreyros will discuss the history of the 340B Program, how it got to its current state, the latest data on hospital use of the program, and how we can fix this program so its results match its intentions.

This discussion will be part of our virtual CPAN Advocacy Chats series – short, monthly educational webinars on key cancer issues and the policies that impact them. Each month will feature a new topic and special guests joining us. Patients, survivors, caregivers, and other cancer care advocates are all invited to join us for these free, interactive, virtual events!

Register Here! Don’t miss out on the 12:00PM chat on October 12th.

This event will be part of our virtual CPAN Advocacy Chats series – short, monthly educational webinars on key cancer issues and the policies that impact them. Each month will feature a new topic and special guests joining us. Patients, survivors, caregivers, and other cancer care advocates are all invited to join us for these free, interactive, virtual events!

View Slides

Get the latest cancer policy news and updates

Get the Latest CPAN News

& Updates

    Sign Up For COA Emails